TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+14.35%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.65B
AUM Growth
+$2.65B
(+8.4%)
Cap. Flow
-$85M
Cap. Flow
% of AUM
-3.21%
Top 10 Holdings %
Top 10 Hldgs %
39.13%
Holding
181
New
13
Increased
25
Reduced
35
Closed
9
Top Buys
| 1 |
Eli Lilly
LLY
|
$17.7M |
| 2 |
Pfizer
PFE
|
$16.7M |
| 3 |
Biogen
BIIB
|
$13.8M |
| 4 |
McKesson
MCK
|
$12.3M |
| 5 |
Avantor
AVTR
|
$9.69M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$36.3M |
| 2 |
Johnson & Johnson
JNJ
|
$25.5M |
| 3 |
Humana
HUM
|
$18.1M |
| 4 |
AstraZeneca
AZN
|
$17M |
| 5 |
Molina Healthcare
MOH
|
$15.2M |
Sector Composition
| 1 | Healthcare | 97.55% |
| 2 | Real Estate | 1.68% |
| 3 | Industrials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$281B
| $143M | 5.42% | 270,546 -3,500 | -1% | -$1.86M |
|
2
Amgen
AMGN
$155B
| $134M | 5.05% | 508,676 -10,193 | -2% | -$2.68M |
|
3
Gilead Sciences
GILD
$140B
| $130M | 4.9% | 1,510,440 -111,725 | -7% | -$9.59M |
|
|
4
Johnson & Johnson
JNJ
$427B
| $113M | 4.27% | 639,679 -144,100 | -18% | -$25.5M |
|
|
5
Eli Lilly
LLY
$657B
| $106M | 3.99% | 288,917 +48,339 | +20% | +$17.7M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $95.4M | 3.6% | 330,343 +16,940 | +5% | +$4.89M |
|
7
Regeneron Pharmaceuticals
REGN
$61.5B
| $87.2M | 3.29% | 120,862 +11,800 | +11% | +$8.51M |
|
8
AbbVie
ABBV
$372B
| $77.3M | 2.92% | 478,342 -48,500 | -9% | -$7.84M |
|
9
Abbott
ABT
$231B
| $76.1M | 2.87% | 693,051 -98,000 | -12% | -$10.8M |
|
|
10
Pfizer
PFE
$141B
| $74.7M | 2.82% | 1,457,170 +325,067 | +29% | +$16.7M |
|
|
11
AstraZeneca
AZN
$248B
| $69.3M | 2.62% | 1,022,255 -250,938 | -20% | -$17M |
|
12
Illumina
ILMN
$15.8B
| $64.7M | 2.44% | 319,958 +25,015 | +8% | +$5.06M |
|
13
Merck
MRK
$210B
| $61.3M | 2.31% | 552,122 | – | – |
|
14
Cigna
CI
$80.3B
| $60.5M | 2.29% | 182,631 -28,100 | -13% | -$9.31M |
|
|
15
Biogen
BIIB
$19.4B
| $54.1M | 2.04% | 195,430 +49,991 | +34% | +$13.8M |
|
16
Thermo Fisher Scientific
TMO
$186B
| $51.6M | 1.95% | 93,705 | – | – |
|
17
Bristol-Myers Squibb
BMY
$96B
| $49.5M | 1.87% | 687,529 -191,947 | -22% | -$13.8M |
|
18
Moderna
MRNA
$9.37B
| $47.6M | 1.8% | 264,927 -49,997 | -16% | -$8.98M |
|
|
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $47.2M | 1.78% | 415,053 -319,300 | -43% | -$36.3M |
|
20
Stryker
SYK
$150B
| $40.1M | 1.52% | 164,128 -29,400 | -15% | -$7.19M |
|
|
21
Humana
HUM
$36.5B
| $39.8M | 1.5% | 77,713 -35,291 | -31% | -$18.1M |
|
22
Boston Scientific
BSX
$156B
| $35M | 1.32% | 757,015 -38,200 | -5% | -$1.77M |
|
23
Alnylam Pharmaceuticals
ALNY
$58.5B
| $34M | 1.29% | 143,214 | – | – |
|
24
Zimmer Biomet
ZBH
$21B
| $33M | 1.25% | 258,868 | – | – |
|
25
United Therapeutics
UTHR
$13.8B
| $32M | 1.21% | 115,077 -2,300 | -2% | -$640K |
|